Amycretin is a novel single-molecule peptide drug that combines two covalently linked analogues of GLP-1 and amylin, creating a dual agonist of the GLP-1 and amylin receptors. Its structure enhances both appetite regulation and metabolic control. By activating GLP-1 pathways to reduce hunger and amylin pathways to slow gastric emptying and improve satiety, amycretin supports powerful, sustained weight reduction.
Research Applications:
- Activates GLP-1 and amylin pathways to support metabolic regulation.
- Helps reduce appetite and enhance satiety signals.
- Slows gastric emptying to aid weight-management efforts.
- Investigated for obesity and broader metabolic health applications.
